Universität zu Köln

Hillmen, Peter, Brown, Jennifer R., Eichhorst, Barbara F., Lamanna, Nicole ORCID: 0000-0003-3331-9491, O'Brien, Susan M., Qiu, Lugui, Salmi, Tommi, Hilger, James, Wu, Kenneth, Cohen, Aileen, Huang, Jane and Tam, Constantine S. (2020). ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol., 16 (10). S. 517 - 524. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Full text not available from this repository.

Abstract

Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hillmen, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Brown, Jennifer R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lamanna, Nicole UNSPECIFIED orcid.org/0000-0003-3331-9491 UNSPECIFIED O'Brien, Susan M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Qiu, Lugui UNSPECIFIED UNSPECIFIED UNSPECIFIED Salmi, Tommi UNSPECIFIED UNSPECIFIED UNSPECIFIED Hilger, James UNSPECIFIED UNSPECIFIED UNSPECIFIED Wu, Kenneth UNSPECIFIED UNSPECIFIED UNSPECIFIED Cohen, Aileen UNSPECIFIED UNSPECIFIED UNSPECIFIED Huang, Jane UNSPECIFIED UNSPECIFIED UNSPECIFIED Tam, Constantine S. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-338807
DOI:	10.2217/fon-2019-0844
Journal or Publication Title:	Future Oncol.
Volume:	16
Number:	10
Page Range:	S. 517 - 524
Date:	2020
Publisher:	FUTURE MEDICINE LTD
Place of Publication:	LONDON
ISSN:	1744-8301
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language VENETOCLAX Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/33880